In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that the anticipated price reductions of up to 70% will dramatically… read more.
Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2… read more.
A new cohort study suggests that when primary care clinicians—rather than specialists—start patients on continuous glucose monitoring (CGM), the benefits are substantial and measurable. Published in JAMA Network… read more.
A new “secret shopper” study published in JAMA has raised concerns about the oversight of online vendors prescribing glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the popular class of… read more.
A trial led by University of Pittsburgh researchers and published today in The Lancet Diabetes & Endocrinology adds nuance to the question of whether older human insulins are as effective as insulin analogues… read more.
Immedica Pharma AB is pleased to announce that the UK MHRA has approved Efmody (modified-release hydrocortisone) for the treatment of adrenal insufficiency in adolescents aged 12 years and… read more.
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications, according to a… read more.
MannKind Corporation announced that the FDA has approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and… read more.
Only a small number of men who were prescribed testosterone therapy received appropriate, guideline-concordant diagnostic testing, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual… read more.
Novo Nordisk presented post hoc analyses from the SELECT, STEP, ESSENCE, and OASIS clinical trials at the 2026 Scientific Sessions of the American Diabetes Association (ADA), highlighting data regarding the impact… read more.
Abbott announced it has secured CE Mark for the world’s first dual glucose‑ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day,… read more.
An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic patients before symptoms occur, according to a study published June… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
